PARP1 and stroke disorder: Several clinically relevant neuroprotective agents that are in development for the treatment of stroke and HIE have shown clear sexual dimorphic responses i.e., PARP inhibitors[4], erythropoietin [23] hypothermia [24] and caspase inhibitors [22].